Preclinical Oncology Services Limited (PRECOS), the oncology-focused research and development provider spun out from the University of Nottingham’s Academic Unit of Cancer Studies, has signed a global master services agreement with Janssen Pharmaceutica (Johnson & Johnson).

The agreement is a consolidation of the working relationship between the two companies that was first established more than five years ago, when PRECOS was a specialist business unit of the University of Nottingham in the UK.

Under the contract, PRECOS will supply clinical tumour materials, tumour model development, target validation and drug efficacy services in support of Janssen’s oncology drug discovery, development and biomarker programmes.

The contract also consolidates PRECOS’ “evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering highly specialist services in the development of new anticancer drugs”, commented chief scientific officer Professor Sue Watson.